anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors have reformed the treatment landscape for various malignancies and improved prognosis of patients. However, they also lead to events that although rare may prove to be fatal.
RESEARCH DESIGN AND METHODS: Data from July 2014 to June 2022 based on FDA Adverse Event Reporting System (FAERS) were analyzed. The signal index reporting odds ratio (ROR) was used to evaluate the correlation between cardiac AEs and given medications. The indications and the median time to onset (TTO) of different PD-1/PD-L1 inhibitors were compared.
RESULTS: Cardiac AEs are rare but may be fatal with particular profiles in primary tumor, onset time, and especially gender. We identified 11,538 reports that were related to cardiotoxicity of PD-1/PD-L1 inhibitors, in which 178 different preferred terms (PTs) were distinguished, and nivolumab reported the most PTs with signal. All targeted medications showed signals in myocardial disorders and pericardial disorders, which tend to occur in the first 1-2 months. Non-small cell neoplasm was the top and common indication during anti-PD-1 or anti-PD-L1 therapy with cardiotoxicity.
CONCLUSIONS: This study could help early diagnosis and surveillance of ICIs-related cardiotoxicity.
IgG4-related disease is an immune-mediated disease that can lead to substantial morbidity and organ damage. Capable of affecting nearly any organ system or anatomic site, and showing considerable overlap in clinical presentation with various other diseases, IgG4-related disease often poses a diagnostic challenge for clinicians. Furthermore, there are no diagnostic biomarkers with high specificity for IgG4-related disease, and histopathological examination is nuanced and requires clinical correlation for accurate diagnosis. Therefore, it is crucial for clinicians to recognise the clinical phenotypes of IgG4-related disease. The disease is generally considered to have predominantly fibrotic and proliferative (or inflammatory) manifestations, with distinct clinical, serological and histopathological findings associated with each manifestation. However, the fibrotic and proliferative manifestations of this disease frequently occur together, thereby blurring this dichotomous distinction. In this Series paper, we provide a detailed overview of the clinical manifestations typical of the proliferative features of IgG4-related disease, with an emphasis on the diagnostic evaluation and differential diagnosis of each proliferative disease manifestation. In addition, we summarise the immune mechanisms underlying IgG4-related disease, suggest a framework for how to approach management and monitoring after the diagnosis is established, and highlight current unmet needs for patient care surrounding this disease.
The invention discloses patient follow-up analysis. A computer-implemented method for comparing subsequent medical findings is provided. The method comprises the following steps: receiving image data showing a body part of a patient at a first time; and retrieving reference data associated with the image data from a database. The reference data includes reference biometric data and one or more reference medical findings. Thereby, the reference biometric data and the one or more reference medical findings are extracted from reference image data describing the body-part of the patient at a second time different from the first time. The method also includes processing the received image data to extract biometric data and one or more medical findings from the image data corresponding to the reference biometric data. Further, the method includes performing a registration of the extracted biometric data with reference biometric data. Subsequently, the extracted medical findings are compared with reference medical findings using registration.
The present invention also provides a method for making the antimicrobial plant fibers. The characteristic of the method is no need of additional reducing agent. The present invention provides plant fibers with antimicrobial effects. The antimicrobial antifungal effect of the fibers is derived from nanosilver particles (diameter between 1 and 100 nm) which are attached to the fibers. The fibers which are made of cotton, linen, blending fibers, or any combination thereof. The fibers can be used to make yarn cloth to be used particularly for treating patients with burns or wound. The cloth made from the antimicrobial fibers can be further used to make clothes such as underwears, socks, shoe cushions, shoe linings, bed sheets, pillow cases, towels, women hygiene products, laboratory coats, and medical robes.
The gut microbiota is a set of microorganisms that inhabit the human digestive tract and are fundamental for the health of the host. Among the functions of the gut microbiota is the production of metabolites, such as the production of secondary bile acids from primary bile acids. On the other hand, evidence has shown that the amount of protein intake can modify the composition of the gut microbiota and in turn it increase the concentration of secondary biles acids in animal models. In addition, the consumption of a high-protein diet has been related to a decrease in postprandial glucose concentrations. Therefore, the aim of this study is to evaluate changes in secondary bile acids concentration derived from gut microbiota after the consumption of a high-protein diet in healthy subjects. Subjects with a BMI between 18.5 and 24.9 kg/m2 will be selected and will be continuously monitored with a continuous glucose monitor through 15 days. During the first 7 days participants will follow an isocaloric diet (50% carbohydrates, 30% fat and 20% protein), while during the last 7 days participants will receive an intervention with a supplement of protein (calcium caseinate) which will increase their protein intake to 30% of the total energy requirement. At the initial and final visit, blood samples will be taken for determination of biochemical parameters, amino acids and primary bile acids and a stool sample will be requested for sequencing gut microbiota and determined secondary bile acids.
Clinical end-point trials have demonstrated that lowering cholesterol levels with statins reduces the incidence of cardiovascular events and mortality. Subgroup analyses of the large clinical studies, the West of Scotland Coronary Prevention (WOSCOP) and Cholesterol and Recurrent Events (CARE), have suggested that the beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. A variety of mechanisms accounting for these effects have been suggested. Among these, the anti-inflammatory activity is particularly attractive because inflammation is considered an early step in the development of atherosclerosis. Thus, statin therapy has been shown to lower high-sensitivity C-reactive protein (CRP), a plasma marker of inflammation, in hypercholesterolemic patients. Furthermore, statins may possess anti-inflammatory properties by their ability to reduce the number of inflammatory cells in atherosclerotic plaques. Red Yeast Rice contains Lovastatin and lowers LDL-cholesterol. However, it is not known to what degree Red Yeast Rice may lower LDL-cholesterol in a European population. Some reports have suggested an effect of Red Yeast Rice on fasting blood glucose by an unknown mechanism.
Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
ARACOMPLEX® (food supplement). 2 tablets per day, during 6 months.
The invention discloses a rivastigmine cutaneous penetration system which comprises an acrylic pressure sensitive adhesive composition of (meth)acrylate, a penetration enhancer, an antioxidant and active medicine. The acrylic pressure sensitive adhesive composition of (meth)acrylate is composed of the mixture of at least one of acrylic pressure sensitive adhesives of (meth)acrylate containing hydroxyl and at least one of polyvinylpyrrolidone or polyalkyl methacrylate copolymer. The penetration enhancer is composed of ethylene glycol monoethyl ether and at least one of lactic acid or lactate compounds. The antioxidant is at least one of alpha-tocopherol, vitamin C palmitate or 2,6-Di-tert-butyl -p-cresol (BHT). The active medicine is rivastigmine or pharmaceutically acceptable salt thereof. The rivastigmine cutaneous penetration system is relatively simple in preparation process, high in cutaneous releasing speed and capable of keeping the enough stability, and patch products with the smaller area can be prepared.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin exhibiting excellent skin chapping preventing and improving effect and moisture-retaining effect and having excellent usability by using tranexamic acid having chapped skin improving effect in combination with a specific compound. SOLUTION: Tranexamic acid is used in combination with a low molecular weight betaine. The low molecular weight betaine is preferably a quaternary ammonium salt expressed by the formula (R<1> to R<3> are each a 1-6C alkyl; (n) is 0 or a positive integer; the total of the sum of the carbon numbers of R<1> to R<3> and (n) is <=8). The amount of tranexamic acid compounded in the total preparation is 0.005-20wt.%, especially 0.01-10wt.% and that of the low molecular weight betaine is 0.01-30wt.%, especially 0.1-20wt.%. The most preferable low molecular weight betaine is trimethylglycine. The preparation for external use for skine gives suppressed powdery feeling caused by the compounded low molecular weight betaine.
A system is described that allows for the tracking of an exercise occurring within a physical environment. In one or more implementations, the system includes a depth sensing device configured to obtain depth values associated with a plurality of pixels. The depth values indicating distances from one or more physical objects in a physical environment to the depth sensing device. The system also includes a computing device in communication with the depth sensing device. The computing device includes a memory and a processor. The processor is configured to execute the one or more modules to cause the processor to: identify a point corresponding to at least one pixel representing a portion of at least one physical object within the physical environment based upon the pixel depth values; track the point through a plurality of image frames; and determine whether at least one repetition has occurred based upon the tracked point.
There is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The method comprises administering to a subject an effective amount of a composition containing hydroxyethyl starch, dextran or hydroxyethyl starch and dextran. The compositions contain these macromolecules in a molecular size and concentration to effectively seal the capillary junctions and stabilize the capillary membranes. The sealant effect is accomplished by a biophysical process due to the adhesiveness and configuration of the macromolecules, and because of their size. There is also provided a means of treating viral and other bacterial infections and cancer, by introducing into the composition of polysaccharide(s) a biological agent, preferably interleukin-2. In certain instances of viral infections associated with human cancers it may be possible to prevent the appearance of malignancy by pretreating with these compositions. In addition other agents, antioxidants, may be included in these compositions.
If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m\^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m\^2) and cyclophosphamide (440 mg/m\^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
A region of interest of a subject is scanned with ultrasound to acquire echo signals. The echo signals are processed to obtain doppler signals. The doppler signals are processed to obtain color angio signals reflecting an amplitude of the doppler signals. The maximum value of levels of the color angio signals is increased from a first value to a second value by a contrast-enhancement effect. The level change within the first value is expressed by the brightness gradation. The level change the first value is expressed by the hue gradation. Therefore, the range less than the first value can be associated with the whole width of the usable brightness gradation of a color display, so that the level change less than the first value can be expressed with high contrast.
BACKGROUND AND AIMS: An acute depletion of circulating haematopoietic stem/progenitor cells (HSPCs) occurs during COVID-19, especially among patients with a poorer disease course. We herein examined whether HSPCs levels at hospital admission for COVID-19 predict 1-year mortality and the long-COVID syndrome.
MATERIALS AND METHODS: Patients hospitalized for COVID-19 in an infectious disease ward were consecutively enrolled. Circulating HSPC levels were assessed by flow cytometry as cells expressing CD34 and/or CD133. Follow-up was performed for 12 months after hospitalization through the review of electronic medical records and demographic local registers.
RESULTS: The study included 100 patients, 36 of whom reported symptoms of long-COVID and 20 died during follow-up. The reduction of 1-SD of HSPCs was associated with a 3- to 5-fold increase in the risk of 1-year mortality. Age, admission hyperglycaemia, C-reactive protein peak, liver enzymes, the need of high-flow oxygen and/or invasive ventilation were predictors of mortality at univariate analysis. Among pre-existing comorbidities, coronary heart disease and chronic kidney disease, but not diabetes, were associated with 1-year mortality. In multivariate analyses, HSPCs remained significantly associated with 1-year mortality independently of confounders. The development of pneumonia an in-hospital treatment with glucocorticoids and convalescent plasma were associated with long-COVID symptoms at follow-up. HSPCs, diabetes and other comorbidities were not predictors of long-COVID.
CONCLUSIONS: In a cohort of patients hospitalized for COVID-19, lower HSPC levels at the time of admission were independent predictors of 1-year mortality. However, COVID-19 severity, but not HSPC level, was significantly associated with the development of long-COVID symptoms.
As Positive Masculinity (PM) Programmes continue to develop globally, it is important to examine their role in Sexual and Reproductive Health and Rights (SRHR) outcomes. This multi-country qualitative study was conducted using in-depth interviews (IDI) and focus group discussions (FGDs) with community members, beneficiaries and implementers of PM programmes. The findings show that PM programmes are designed using a gender lens to make boys and men more aware and conscious of harmful masculinity traits and their effect on SRHR. The beneficiaries of the interventions report imbibing positive SRHR behaviours by being sexually responsible - upholding sexual rights, taking precautions against sexually transmitted Infections (STIs) and learning proper communication with their partners. They also report acting as vanguards of positive gender norms to their families and peers. Although there are challenges in implementing PM programmes, the results of the study suggest that interventions targeting boys and men hold promise for improving boys' and men's health behaviours and promoting gender equality in poor urban settings.
The SupraGlio-AI study aims to test the feasibility of the proposed AI-guided tailored supratotal resection for glioblastomas. The study will provide preliminary data on the accuracy of the AI model in predicting recurrence and the impact of using this information in surgical planning. This information will be crucial in determining the potential for a larger, randomized controlled trial in the future. The pilot study will also allow for refinement of the study design, intervention, and data collection processes before a larger-scale study is conducted. In addition to testing the feasibility and efficacy of the AI-guided tailored supratotal resection, this pilot study also has two secondary objectives: 1) Survival Analysis: A survival analysis will be performed to compare the prospective cohort of patients undergoing the AI-guided procedure with a retrospective cohort of glioblastoma patients who underwent standard gross total resection. The survival analysis will provide insights into the impact of using the AI model on patient outcomes and help determine the potential benefits of this approach. 2) Histopathological and Transcriptomic Analysis: The study will also include a histopathological and transcriptomic analysis of the tissue samples obtained from the high-risk regions defined by the AI model. This analysis will provide information on the molecular and cellular changes occurring in these regions and may offer insights into the underlying biology of glioblastoma recurrence. These data will inform the development of future studies aimed at improving patient outcomes.

By incorporating these secondary objectives, this pilot study will contribute to a more comprehensive understanding of the potential benefits of using AI in guiding tailored supratotal resection for glioblastomas. The results will inform future research and potentially lead to the development of improved treatment approaches for patients with this type of brain tumor.
The present invention provides a hydrogel composition, preferably for the treatment of wounds, comprising a hydrophilic co-polymer carrying multiple pendant anionic groups, wherein the polymer is derived from a first monomer and a second monomer, wherein both monomers have an octanol:water partition coefficient LogP value of less than 0, and, the LogP value of the first monomer is greater (more positive) than the second monomer. The difference between the LogP value for the two monomers is preferably less than 2. The weight ratio (w/w) of the first monomer/second monomer in the hydrogel composition is preferably equal to or more than about 1. The pendant anionic groups may be sulphonyl groups, e.g. sulphonic acid groups or salts thereof. The anionic group in both first and second monomers may be in salt form and the counterion for both monomers is preferably the same.
OBJECTIVE: Fetuses with abnormal karyotypes often exhibit distinctive ultrasonographic markers, including major anomalies and "soft" markers, indicating potential chromosomal issues. A crucial consideration arises when a single fetal anomaly is detected, raising the question of whether karyotyping is warranted, given the associated procedural risks. Our objective was to establish correlations between single fetal anomalies identified through ultrasound and chromosomal abnormalities.
METHODS: A cross-sectional study analyzed the karyotype of 1493 fetuses and detected a single ultrasonographic anomaly over a 16-year period. Karyotyping was performed using the standard karyotype technique. Moreover, data regarding the type of anomaly detected ultrasonographically, karyotype results, and outcomes following interventions were collected. Among other methods, the use of positive likelihood ratios (LR+) was used to evaluate the diagnostic accuracy of ultrasound compared to karyotyping.
RESULTS: In total, an aberrant karyotype was identified in 99 fetuses (6.6%). This was most commonly observed in cases involving a "soft" marker, occurring in 27 out of 218 fetuses (12.4%). The most frequently detected aberrant karyotype resulted from aneuploidies (80.6% of cases), notably trisomy 21 (50.5%). "Soft" markers predicted chromosomal issues (LR+ = 1.9; OR = 2.4), and isolated polyhydramnios (LR+ = 1.54; OR = 1.6) showed significance in predicting fetal chromosomal aberrations.
CONCLUSION: When assessing the necessity for karyotyping in fetuses with single major anomalies or "soft" markers, it is crucial to consider individual risks for chromosomopathies, including the LR+ of the detected marker. In cases where fetuses exhibit isolated anomalies with a normal karyotype, additional diagnostic measures, such as molecular cytogenetic and molecular genetics techniques, may become necessary.
PURPOSE:To obtain an antirheumatic agent having high pharmacological effect and low side action by using SAIREITO (a kind of blended Chinese herb drugs) as an active component. CONSTITUTION:SAIREITO composed of 4-7 pts. of SAIKO (root of Bupleurum falcatum), 5-6 pts of TAKUSHA (bulb of Alisma plantago-aquatica), 4-5 pts. of HANGE (rhizome of Pinellia ternata), 3 pts. of OUGON (root of Scutellaria baicalensis), 3-4.5 pts. of SOUJUTSU (rhizome of Atractylodes lancea), 2-3 pts. of DAISOU (fruit of Zizyphus jujuba), 3-4.5 pts. of CHOREI (sclerotium of Polyporus umbellatus), 2-3 pts. of NINJIN (rhizome of Panax ginseng), 3-4.5 pts. of BUKURYO (sclerotium of Poria cocos), 2 pts. of KANZOU (root of Glycyrrhiza glabra), 2-3 pts. of KEIHI (bark of Cinnamomum cassia) and 1-4 pts. of SHOUKYOU (rhizome of Zingiber officinale) is used as it is or the extract SAIREITO is used as an active component. The agent is prepared in the form of peroral drug or a parenteral drug such as injection and drip. The daily dose of the agent is 1-10g (in terms of dried extract of the SAIREITO) for adult in 1-3 divided doses in the case of peroral administration. The SAIREITO extract can be prepared by extracting the SAIREITO having the above composition with 10-20 times volume of hot water and filtering the extracted solution.
The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
Patients will be assessed before (baseline), 4 (visit 2) and 12 weeks (visit 3) after use of Medical cannabis via inhaled dried buds or sublingual oil extract. The percentage of THC and CBD were pre-set to 10% and 2%, respectively. All patients received the same general instructions for treatment titration, which was to start with 1 drop or puff a day and increase by 1 drop or puff as needed. There was no fixed schedule for the incremental increases, thus each patient freely raised the dose as well as number of daily consumptions until clinical benefit was achieved or SE emerged over a follow-up period of 12 weeks.
Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.